615 related articles for article (PubMed ID: 29748390)
1. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
2. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.
Martini DJ; Hamieh L; McKay RR; Harshman LC; Brandao R; Norton CK; Steinharter JA; Krajewski KM; Gao X; Schutz FA; McGregor B; Bossé D; Lalani AA; De Velasco G; Michaelson MD; McDermott DF; Choueiri TK
Cancer Immunol Res; 2018 Apr; 6(4):402-408. PubMed ID: 29437040
[TBL] [Abstract][Full Text] [Related]
3. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
5. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK
J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
[TBL] [Abstract][Full Text] [Related]
10. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
McDermott DF; Lee JL; Ziobro M; Suarez C; Langiewicz P; Matveev VB; Wiechno P; Gafanov RA; Tomczak P; Pouliot F; Donskov F; Alekseev BY; Shin SJ; Bjarnason GA; Castellano D; Silverman RK; Perini RF; Schloss C; Atkins MB
J Clin Oncol; 2021 Mar; 39(9):1029-1039. PubMed ID: 33529058
[TBL] [Abstract][Full Text] [Related]
11. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
Ahrens M; Scheich S; Hartmann A; Bergmann L;
Oncol Res Treat; 2019; 42(3):128-135. PubMed ID: 30799404
[TBL] [Abstract][Full Text] [Related]
12. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.
Ascierto ML; McMiller TL; Berger AE; Danilova L; Anders RA; Netto GJ; Xu H; Pritchard TS; Fan J; Cheadle C; Cope L; Drake CG; Pardoll DM; Taube JM; Topalian SL
Cancer Immunol Res; 2016 Sep; 4(9):726-33. PubMed ID: 27491898
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma.
Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T
Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410
[TBL] [Abstract][Full Text] [Related]
15. A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.
Nunes-Xavier CE; Angulo JC; Pulido R; López JI
Curr Urol Rep; 2019 Jan; 20(1):1. PubMed ID: 30645700
[TBL] [Abstract][Full Text] [Related]
16. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract][Full Text] [Related]
17. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 detection using
Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
[TBL] [Abstract][Full Text] [Related]
19. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
[TBL] [Abstract][Full Text] [Related]
20. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
